However, several proteins overexpressed in tumor cells have been tested as targets for CAR cell therapy [175], including mesothelin (MSLN), a membrane glycoprotein expressed in normal mesothelial tissues but highly expressed in various malignancies, such as non-small-cell lung cancer (NSCLC) and ovarian cancer. Here, MSLN is linked to ovarian cancer.